ERBB2 and breast cancer: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 −) breast cancer is the most common subtype, with an estimated annual incidence rate of 87.0/100,000 women during 2013–2017 in the US [1, 2].